| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net sales | 426,175 | 385,641 | 507,755 | 445,970 |
| Cost of sales | 77,887 | 66,867 | 81,358 | 93,514 |
| Gross profit | 348,288 | 318,774 | 426,397 | 352,456 |
| Distributors incentives | 1,658 | 2,343 | 2,316 | 2,987 |
| Selling, general and administrative (including equity compensation granted to officers, directors and contractors of 30,353 in the period ended march 31, 2026 and 75,633 in the period ended march 31, 2025) | 396,394 | 527,089 | 432,540 | 456,728 |
| Amortization expense | NaN | 0* | 0 | NaN |
| Impairment expense | NaN | 725,000* | NaN | NaN |
| Total operating expenses | 398,052 | 1,254,432 | 434,856 | 459,715 |
| Loss from operations | -49,764 | -935,658 | -8,459 | -107,259 |
| Write-off of accrued liabilities | 81,334 | NaN | NaN | NaN |
| Other income | 19,101 | NaN | NaN | NaN |
| Interest expense and financing costs (including related party interest of 38,088 in the three months ended in march 31, 2026 and 35,455 in march 31, 2025 | 77,086 | 82,147 | 72,106 | NaN |
| Interest expense and financing costs (including related party interest of 35,455 in the six months ended in june 30, 2025 and 31,063 in june 30, 2024 | NaN | NaN | NaN | 71,086 |
| Other income and expense (net) | 23,349 | NaN | NaN | NaN |
| Net loss | -26,415 | -1,017,805 | -80,565 | -178,345 |
| Foreign currency translation adjustment | 0 | 0 | 7,222 | -7,197 |
| Other comprehensive loss | -26,415 | -1,017,805 | -73,343 | -185,542 |
| Basic EPS | 0 | -0.001 | 0 | 0 |
| Diluted EPS | 0 | -0.001 | 0 | 0 |
| Basic Average Shares | 969,173,181 | 961,767,430 | 960,873,144 | 959,205,422 |
| Diluted Average Shares | 969,173,181 | 961,767,430 | 960,873,144 | 959,205,422 |
BIOREGENX, INC. (BRGX)
BIOREGENX, INC. (BRGX)